MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

201.64
+2.81
+1.41%
Opening 14:45 09/22 EDT
OPEN
199.46
PREV CLOSE
198.83
HIGH
202.37
LOW
196.39
VOLUME
75.39K
TURNOVER
--
52 WEEK HIGH
216.90
52 WEEK LOW
98.37
MARKET CAP
9.05B
P/E (TTM)
19.61
1D
5D
1M
3M
1Y
5Y
Insider Sell: United Therapeutics
MT Newswires · 6d ago
United Therapeutics Corp (UTHR) EVP & General Counsel Paul A Mahon Sold $1.2 million of Shares
GuruFocus News · 6d ago
United Therapeutics Releases its Annual Corporate Responsibility Report
and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its second annual Corporate Responsibility Report with 2020 highlights, providing stakeholders important information regarding the company's commitment to ...
PR Newswire - PRF · 09/10 10:00
Steven Cohen Boosts Health Care Exposure With Theravance Biopharma Stake
GuruFocus News · 09/08 20:55
BRIEF-United Therapeutics Presents Tyvaso DPI Breeze Clinical Data At European Respiratory Society International Congress 2021
reuters.com · 09/07 10:42
United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue?
Zacks.com · 09/03 15:31
United Therapeutics Corp (UTHR) EVP & General Counsel Paul A Mahon Sold $1.3 million of Shares
GuruFocus News · 09/02 04:00
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month
and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it is joining forces with former NFL player and his daughter Leah, a survivor of high-risk neuroblastoma, to launch the educational initiative "Braving NeuroBLASToma" sh...
PR Newswire - PRF · 08/25 10:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of UTHR. Analyze the recent business situations of Utd Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average UTHR stock price target is 231.89 with a high estimate of 276.00 and a low estimate of 130.00.
EPS
Institutional Holdings
Institutions: 592
Institutional Holdings: 46.86M
% Owned: 104.38%
Shares Outstanding: 44.89M
TypeInstitutionsShares
Increased
116
2.61M
New
52
1.26M
Decreased
157
3.23M
Sold Out
39
588.05K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.38%
Pharmaceuticals & Medical Research
+0.05%
Key Executives
Chairman/Chief Executive Officer/Director
Martine Rothblatt
President/Chief Operating Officer
Michael Benkowitz
Non-Executive Vice Chairman/Lead Director/Independent Director
Christopher Patusky
Chief Financial Officer/Treasurer
James Edgemond
Executive Vice President/General Counsel/Secretary
Paul Mahon
Independent Director
Christopher Causey
Independent Director
Raymond Dwek
Independent Director
Richard Giltner
Independent Director
Katherine Klein
Independent Director
Raymond Kurzweil
Independent Director
Linda Maxwell
Independent Director
Nilda Mesa
Independent Director
Judy Olian
Independent Director
Louis Sullivan
Independent Director
Thomas Thompson
No Data
About UTHR
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Webull offers kinds of United Therapeutics Corporation stock information, including NASDAQ:UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.